“Cooperation OncoArendi and Galapagos is to, in the next few years, lead to the introduction of a drug based on the OATD-01 molecule or other dual inhibitors to the world markets for in the treatment of idiopathic pulmonary fibrosis (IPF), sarcoidosis, asthma or other interstitial lung diseases. It is worth noting that, according to more and more scientific reports, pulmonary fibrosis is one of the most common complications after COVID-19“- we read in the release.
Szumowski signed a contract for PLN 1.5 billion
According to the agreement, OncoArendi Therapeutics will receive an up-front payment of PLN 25 million. euro. Further tranches under the signed agreement will be disbursed by Galapagos NV once further “milestones” are reached.